RA Capital Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17M | Hold |
848,986
| – | – | 0.29% | 38 |
|
|
2025
Q1 | $16.7M | Hold |
848,986
| – | – | 0.28% | 49 |
|
|
2024
Q4 | $19.1M | Sell |
848,986
-212,247
| -20% | -$4.78M | 0.25% | 57 |
|
|
2024
Q3 | $27.1M | Sell |
1,061,233
-1,061,232
| -50% | -$27.1M | 0.31% | 50 |
|
|
2024
Q2 | $49.6M | Hold |
2,122,465
| – | – | 0.66% | 38 |
|
|
2024
Q1 | $37.3M | Hold |
2,122,465
| – | – | 0.48% | 47 |
|
|
2023
Q4 | $29.4M | Hold |
2,122,465
| – | – | 0.46% | 40 |
|
|
2023
Q3 | $29M | Hold |
2,122,465
| – | – | 0.57% | 46 |
|
|
2023
Q2 | $43.3M | Hold |
2,122,465
| – | – | 0.82% | 36 |
|
|
2023
Q1 | $46.5M | Buy |
2,122,465
+1,309,784
| +161% | +$28.7M | 1.05% | 32 |
|
|
2022
Q4 | $13.3M | Buy |
+812,681
| New | +$13.3M | 0.27% | 49 |
|
|
2021
Q3 | – | Sell |
-62,201
| Closed | -$1.97M | – | 99 |
|
|
2021
Q2 | $1.97M | Hold |
62,201
| – | – | 0.03% | 90 |
|
|
2021
Q1 | $2.1M | Hold |
62,201
| – | – | 0.03% | 81 |
|
|
2020
Q4 | $5.49M | Sell |
62,201
-234
| -0.4% | -$20.6K | 0.08% | 78 |
|
|
2020
Q3 | $5.08M | Sell |
62,435
-144,902
| -70% | -$11.8M | 0.09% | 66 |
|
|
2020
Q2 | $22.9M | Sell |
207,337
-156,250
| -43% | -$17.3M | 0.45% | 39 |
|
|
2020
Q1 | $23.3M | Buy |
+363,587
| New | +$23.3M | 0.74% | 34 |
|